Although there is one GLP-1 medication, Rybelsus, currently given as a daily pill, it has so far only been prescribed as a ...

Instead of struggling with weekly injections, patients may soon be able to swallow a daily pill to lose weight. Both the ...

A major new study has found that a drug called semaglutide can greatly improve heart health in people who are overweight or ...

Scientists have failed to show that weight-loss wonder drug semaglutide slows the progress of Alzheimer's disease (AD), as ...

Shares of Novo Nordisk ( NVO 5.58%) fell on Monday, finishing down 5.6%. The drop comes as the S&P 500 and the Nasdaq ...

The studies were a significant setback for the optimistic view that semaglutide and other GLP-1 drugs could help prevent a ...

The White House plans to release a health-policy framework extending Affordable Care Act premium subsidies. Novo Nordisk's ...

An oral version of semaglutide, the active ingredient in blockbuster drugs Ozempic and Wegovy, failed to slow the progression ...

In the first quarter of 2018, there were less than five postpartum GLP-1 prescriptions, but by the second quarter of 2022, the number rose to 34 per 10,000 and sharply increased to 173 per 10,000 in ...

Two large-scale phase 3 trials found that semaglutide did not significantly slow cognitive decline in early-stage Alzheimer’s ...

Shares in a pharma firm hit a four-year low today as trials revealed its weight loss drug fails to slow the progression of ...

GLP-1 drugs like Wegovy and Zepbound have been racking up sales and new indications, as researchers learn more about how the ...